7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
Learn how Mounjaro (tirzepatide) affects eGFR and kidney function. Review clinical trial data from SURPASS and SURMOUNT programs, monitoring timelines, and what eGFR changes mean for patients on tirzepatide.
Tirzepatide (Mounjaro) can lower AST in many patients by reducing hepatic steatosis, but transient AST elevations also occur. Learn the clinical data, monitoring schedule, and what your numbers mean.
Tirzepatide (Mounjaro) changes CGM patterns within weeks. Learn the direction, magnitude, and clinical timeline of CGM shifts on Mounjaro, plus when to adjust monitoring.
Tirzepatide (Mounjaro) lowers fasting plasma glucose by 43 to 65 mg/dL in type 2 diabetes. Learn the mechanism, timeline, trial data from SURPASS-1 through SURPASS-5, and monitoring recommendations.
Tirzepatide (Mounjaro) lowers fasting triglycerides by 19 to 25% in clinical trials. Learn the mechanism, timeline, monitoring schedule, and what the SURPASS data show.
Tirzepatide (Mounjaro) can shift multiple CMP markers including fasting glucose, ALT, AST, creatinine, and electrolytes. Learn the direction, magnitude, and monitoring schedule backed by SURPASS trial data.
Tirzepatide (Mounjaro) measurably shifts triglycerides, LDL cholesterol, and HDL. Learn the magnitude, timing, mechanism, and when to recheck your lipid panel on treatment.